D. Valmori

发表

BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

J. Tschopp, P. Romero, K. Hofmann, 1999, The Journal of experimental medicine.

A peripheral circulating compartment of natural naive CD4 Tregs.

D. Valmori, A. Merlo, Naira E. Souleimanian, 2005, The Journal of clinical investigation.

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.

P. Romero, C. Widmann, D. Valmori, 1992, Journal of immunological methods.

Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1

Danila Valmori, Hans-Georg Rammensee, Pedro Romero, 2002, The Journal of Immunology.

Ectopic Human Telomerase Catalytic Subunit Expression Maintains Telomere Length But Is Not Sufficient for CD8+ T Lymphocyte Immortalization1

P. Romero, M. Amacker, D. Valmori, 2000, The Journal of Immunology.

Subcellular Localization of the Melanoma-associated Protein Melan-AMART-1 Influences the Processing of Its HLA-A2-restricted Epitope*

P. Romero, D. Valmori, K. Muehlethaler, 2001, The Journal of Biological Chemistry.

Lack of tumor recognition by hTERT peptide 540–548‐specific CD8+ T cells from melanoma patients reveals inefficient antigen processing

D. Speiser, P. Romero, D. Valmori, 2001, European journal of immunology.

Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides.

S. Bertholet, D. Valmori, N. Fasel, 1994, Journal of immunology.

Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum.

D. Valmori, C. Servis, N. Fasel, 1995, Journal of immunology.

HLA‐A*0201 restricted CD8+ T‐lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN‐γ ELISPOT

P. Romero, D. Valmori, J. Tiercy, 2000, Parasite immunology.

Correction: Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients

D. Valmori, Kanako Saito, E. Nakayama, 2016, PloS one.

Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients

D. Valmori, Kanako Saito, E. Nakayama, 2016, PLoS ONE.

Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells

D. Valmori, M. Ayyoub, P. Pignon, 2015, European journal of immunology.

Immune monitoring in cancer immunotherapy.

D. Speiser, P. Romero, V. Cerundolo, 2000, Ernst Schering Research Foundation workshop.

Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.

D. Speiser, P. Romero, V. Cerundolo, 1999, Cancer research.

Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.

D. Speiser, P. Romero, D. Valmori, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1

D. Speiser, P. Romero, M. Pittet, 2001, The Journal of Immunology.

Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.

D. Schadendorf, E. Thiel, P. Romero, 2002, Cancer research.

Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.

P. Romero, I. Miconnet, D. Valmori, 1999, Journal of immunology.

An antigen-targeted approach to adoptive transfer therapy of cancer.

P. Romero, V. Cerundolo, D. Valmori, 1999, Cancer research.

Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

D. Speiser, P. Romero, N. Rufer, 2002, Immunological reviews.

Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo.

S. Hoffman, H. Grey, A. Sette, 1997, Vaccine.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

C. Porta, L. Zitvogel, A. Eggermont, 2014, Cancer research.

Regulation of CD 4 + NKG 2 D + Th 1 cells in patients with metastatic melanoma treated with Sorafenib : role of IL-15 R α and NKG 2 D triggering

C. Porta, L. Zitvogel, A. Eggermont, 2013 .

HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine

L. Old, D. Valmori, B. Dupont, 2009, Clinical Cancer Research.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

S. Vogel, S. Adams, A. Pavlick, 2007, Proceedings of the National Academy of Sciences.

The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

M. Mansukhani, H. Hibshoosh, L. Memeo, 2004, Cancer immunity.

Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers.

L. Memeo, V. Canzonieri, D. Valmori, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells

K. Odunsi, L. Old, D. Valmori, 2006, Clinical Cancer Research.

CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg

K. Odunsi, D. Valmori, M. Ayyoub, 2013, Cancer Immunology Research.

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

P. Wallace, R. Cheney, K. Odunsi, 2009, Cancer research.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers

D. Valmori, M. Ayyoub, I. Luescher, 2010, Proceedings of the National Academy of Sciences.

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

D. Speiser, P. Romero, O. Michielin, 2005, Cancer treatment and research.

CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.

D. Speiser, P. Romero, D. Valmori, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunodominant Peptide Analogues CTL In Vitro by Selected Melan-A/MART-1 Enhanced Generation of Specific Tumor-Reactive

D. Valmori, F. Jotereau, J. Cerottini, 2017 .

Antigenic Peptide Immunodominant Melan-A/MART-1 HLA-A*0201-Restricted CTL Specific for the Diversity of the Fine Specificity Displayed by

P. Romero, D. Valmori, F. Jotereau, 1998 .

Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors

L. Old, D. Valmori, N. Bhardwaj, 2009, Journal of immunotherapy.

Differential expression of HLA-A*02 subtypes in Colombian Blacks and Mestizos.

D. Valmori, C. Bordignon, S. Herrera, 2008, Tissue antigens.

CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria.

P. Romero, D. Valmori, G. Eberl, 1995, Immunology letters.

Induction of a cytotoxic T cell response by co‐injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre‐injection of IFA alone

P. Romero, D. Valmori, J. Maryanski, 1994, European journal of immunology.

Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs.

K. Odunsi, L. Old, D. Valmori, 2008, Clinical immunology.

Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue

P. Romero, V. Cerundolo, I. Miconnet, 2000, The Journal of Immunology.

Encoding a MelanA Peptide Analogue Responses by Recombinant Vaccinia Induction of Potent Antitumor CTL

V. Cerundolo, I. Miconnet, D. Valmori, 1999 .

Lymphocyte Immortalization T + Length But Is Not Sufficient for CD 8 Subunit Expression Maintains Telomere Ectopic Human Telomerase Catalytic

P. Romero, M. Amacker, D. Valmori, 2000 .

Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.

D. Speiser, P. Romero, D. Valmori, 2003, Cancer research.

Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1

D. Valmori, V. Tosello, Naira E. Souleimanian, 2006, The Journal of Immunology.

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

I. Mellman, W. Garrett, L. Old, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

P. Romero, D. Valmori, F. Jotereau, 1997, Journal of immunology.

Lentivector immunization induces tumor antigen‐specific B and T cell responses in vivo

D. Valmori, S. Colombetti, F. Lévy, 2008, European journal of immunology.

Cross‐presentation of NY‐ESO‐1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells

D. Valmori, T. Kanematsu, H. Udono, 2007, Cancer science.

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.

L. Old, D. Valmori, F. Jotereau, 2006, Clinical immunology.

Peptide‐antibody conjugates for tumour therapy: A MHC‐class‐II‐restricted tetanus toxin peptide coupled to an anti‐IG light chain antibody can induce cytotoxic lysis of a human B‐cell lymphoma by specific CD4 T cells

D. Valmori, J. Mach, G. Corradin, 1994, International journal of cancer.

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer

D. Valmori, M. Ayyoub, I. Luescher, 2013, Haematologica.

Clinical Cancer esearch ing , Diagnosis , Prognosis essment of Vaccine-Induced CD 4 T Cell Responses to the-143 Immunodominant Region of the Tumor-Specific R igen NY-ESO-1 Using DRB 1 * 0101 Tetramers

L. Old, D. Valmori, M. Ayyoub, 2010 .

L. Old, D. Valmori, P. Pignon, 2010 .

Decreased Binding of Peptides-MHC Class I (pMHC) Multimeric Complexes to CD8 Affects Their Binding Avidity for the TCR But Does Not Significantly Impact on pMHC/TCR Dissociation Rate1

D. Valmori, C. Hesdorffer, M. Ayyoub, 2003, The Journal of Immunology.

Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.

D. Speiser, P. Romero, M. Pittet, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Self-Antigen Specific for a Human Tumor-Associated Selection of the Preimmune Repertoire-Chain in the α Prevalent Role of TCR Cerottini

M. Bonneville, P. Romero, P. Coulie, 2003 .

TCR Dissociation Rate But Does Not Significantly Impact on Affects Their Binding Avidity for the TCR ( pMHC ) Multimeric Complexes to CD 8 Decreased Binding of Peptides-MHC Class

D. Valmori, C. Hesdorffer, M. Ayyoub, 2003 .

Dissecting TCR‐MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes

P. Romero, D. Valmori, J. Cerottini, 2002, European journal of immunology.

Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity1

P. Romero, M. Pittet, P. Walker, 2002, The Journal of Immunology.

Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR1

D. Speiser, P. Romero, D. Valmori, 2002, The Journal of Immunology.

Reactivity Increased Functional Avidity and Tumor an Oligoclonal T Cell Population with Vaccination with a MelanA Peptide Selects

P. Romero, M. Pittet, P. Walker, 2002 .

Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.

P. Romero, D. Valmori, J. Cerottini, 2002, Cancer immunity.

This information is current as to TCR Stability of MHC / Peptide Multimer Binding theCTL Recognition Directly Correlates with Functional Avidity of Tumor Antigen-Specific Romero and Danila

D. Speiser, P. Romero, D. Valmori, 2002 .

Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

D. Speiser, P. Romero, D. Valmori, 2001, Cancer research.

Antitumor Activity Avidity-specific Cytolytic T Lymphocytes Show Superior : High 262 − 254 Heterogeneous T-Cell Response to MAGE-A 10 Updated Version

D. Speiser, P. Romero, D. Valmori, 2001 .

Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma

D. Speiser, P. Romero, D. Valmori, 2000, The Journal of Immunology.

Generation and characterization of malaria‐specific human CD8+ lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells

P. Romero, D. Valmori, J. Oberholzer, 2000, European journal of immunology.

Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

D. Speiser, U. Şahin, P. Romero, 2000, Cancer research.

T Cells in Melanoma + Melan-A-Specific CD8 Usage Reveals a Large Repertoire of -Chain b Tetramer-Guided Analysis of TCR

D. Speiser, P. Romero, D. Valmori, 2000 .

CTL Epitopes in Melanoma Nonprimary Open Reading Frame-Derived NY-ESO-1 / LAGE-1 Primary and Efficient Simultaneous Presentation of and Danila

D. Speiser, P. Romero, D. Valmori, 2000 .

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

P. Romero, D. Valmori, J. Cerottini, 1997, Cancer research.

Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.

P. Romero, D. Valmori, J. Cerottini, 2001, Cancer research.

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire

L. Old, D. Valmori, N. Bhardwaj, 2009, Clinical Cancer Research.

Enhanced generation of specific tumor-reactive CTL in vitro by Melan-A/Mart-1 immunodominant peptide analogs

P. Romero, D. Valmori, V. Jongeneel, 1997 .

Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

D. Valmori, E. Bianchi, G. Corradin, 1992, Journal of immunology.

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

L. Old, D. Valmori, Naira E. Souleimanian, 2005, Clinical immunology.

NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment

D. Valmori, D. Berton‐Rigaud, M. Ayyoub, 2011, PloS one.

Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

D. Speiser, P. Romero, V. Cerundolo, 1999, International immunology.

CD4+ T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs

D. Valmori, M. Ayyoub, 2015, Oncoimmunology.

Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival

D. Valmori, M. Ayyoub, P. Pignon, 2014, Journal of immunotherapy.

CD28‐negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients

D. Speiser, P. Romero, V. Cerundolo, 1999, European journal of immunology.

Human Memory Helios− FOXP3+ Regulatory T Cells (Tregs) Encompass Induced Tregs That Express Aiolos and Respond to IL-1β by Downregulating Their Suppressor Functions

D. Valmori, M. Ayyoub, P. Pignon, 2013, The Journal of Immunology.

Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.

J. Schrenzel, D. Speiser, P. Romero, 2007, The Journal of investigative dermatology.

IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.

Yao-Tseng Chen, D. Atanackovic, I. Mellman, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1

Yao-Tseng Chen, D. Atanackovic, L. Old, 2003, The Journal of Immunology.

Nonprofessional APCs from Exogenous NY-ESO-1 Polypeptides by Cross-Presentation of HLA Class I Epitopes

Yao-Tseng Chen, D. Atanackovic, D. Valmori, 2003 .

Advances in Brief Frequent Cytolytic T-Cell Responses to Peptide MAGE-A 10254 – 262 in Melanoma 1

P. Romero, D. Valmori, J. Cerottini, 2001 .

Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles.

P. Matricardi, A. Lanzavecchia, D. Valmori, 1994, Journal of immunology.

Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells1

S. Stevanović, Yao-Tseng Chen, D. Speiser, 2004, The Journal of Immunology.

Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.

D. Speiser, P. Romero, M. Pittet, 2002, Trends in immunology.

A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy1

B. Monsarrat, P. Romero, D. Valmori, 2001, The Journal of Immunology.

Anti-Melanoma Immunotherapy Biodegradation : Implication for Molecular Immunogenicity and High Resistance to Peptides

B. Monsarrat, P. Romero, D. Valmori, 2001 .

CD4+ T Cell Responses to SSX-4 in Melanoma Patients1

S. Stevanović, Yao-Tseng Chen, D. Speiser, 2005, The Journal of Immunology.

CD4 T Cell Responses to SSX-4 in Melanoma Patients

S. Stevanović, Yao-Tseng Chen, D. Speiser, 2005 .

Melanoma Patients T Cell Responses to SSX-4 in + CD 4

S. Stevanović, Yao-Tseng Chen, D. Speiser, 2005 .

Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity

D. Valmori, Kanako Saito, M. Ayyoub, 2015, PloS one.

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia.

C. Scheibenbogen, D. Valmori, U. Keilholz, 2003, Blood.

Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors

D. Valmori, M. Ayyoub, Caroline Raffin, 2010, Proceedings of the National Academy of Sciences.

Using Modified Antigenic Sequences to Develop Cancer Vaccines: Are We Losing the Focus?

D. Valmori, M. Ayyoub, 2004, PLoS medicine.

Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes

D. Valmori, D. Grillot, P. Lambert, 1993, Infection and immunity.

Lack of H‐2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide

D. Valmori, P. Migliorini, P. Lambert, 1991, European journal of immunology.

The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells.

D. Speiser, P. Romero, M. Colonna, 2001, Journal of immunology.

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

Danila Valmori, Pedro Romero, Philippe Guillaume, 2003, Cancer immunity.

Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor RORγt

Danila Valmori, D. Valmori, L. Leveque, 2009, Proceedings of the National Academy of Sciences.

IL-1beta and IL-2 convert human Treg into T(H)17 cells.

D. Valmori, M. Ayyoub, F. Deknuydt, 2009, Clinical immunology.

Identification of HLA‐A2 restricted CD8+ T‐lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria

D. Valmori, S. Herrera, M. Arévalo-Herrera, 2002, Parasite immunology.

Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes.

R A Houghten, R Simon, R. Simon, 2001, Cancer research.

High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

D. Speiser, P. Romero, V. Cerundolo, 1999, The Journal of experimental medicine.

Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression1

D. Speiser, P. Romero, M. Pittet, 2000, The Journal of Immunology.

The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector αβ T Cells1

D. Speiser, P. Romero, M. Colonna, 2001, The Journal of Immunology.

Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals

S. Stevanović, D. Valmori, M. Ayyoub, 2007, Cancer Immunology, Immunotherapy.

Consensus nomenclature for CD 8 T cell phenotypes in cancer

S. H. van der Burg, J. Blay, F. Marincola, 2015 .

Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

P. Romero, D. Valmori, F. Jotereau, 1998, Journal of immunology.

Application of support vector machines for T-cell epitopes prediction

Yingdong Zhao, Clemencia Pinilla, Danila Valmori, 2003, Bioinform..

The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production1

C. Rüegg, D. Valmori, M. D. Puente Navazo, 2001, The Journal of Immunology.

Production Lymphocyte Proliferation and Cytokine Tenascin-C Suppresses Activation-Induced T A 1 A 2 of the Extracellular Matrix Protein The Alternatively Spliced Domain TnFnIII

C. Rüegg, D. Valmori, Marta Navazo, 2001 .

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

J. Douillard, D. Valmori, M. Ayyoub, 2012, Cancer research.

In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma–Specific Cytolytic T Lymphocytes

D. Speiser, P. Romero, V. Cerundolo, 1999, The Journal of experimental medicine.

Final Antigenic Melan-A Peptides Produced Directly by the Proteasomes Are Preferentially Selected for Presentation by HLA-A*0201 in Melanoma Cells1

B. Monsarrat, P. Romero, D. Valmori, 2004, The Journal of Immunology.

HLA-A * 0201 in Melanoma Cells Preferentially Selected for Presentation by Directly by the Proteasomes Are Final Antigenic MelanA Peptides Produced Romero and Frédéric Lévy Burlet

B. Monsarrat, P. Romero, D. Valmori, 2004 .

HLA-associated immunodominance and responsiveness to cancer vaccines

D. Valmori, 2008 .

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

G. Ogg, P. Romero, V. Cerundolo, 1998, The Journal of experimental medicine.

A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes.

Clemencia Pinilla, Danila Valmori, Richard Simon, 2004, Molecular immunology.

show telomerase activity and are distinct from cytolytic effector T cells

D. Speiser, P. Romero, D. Valmori, 2001 .

Ex Vivo IL-1 Receptor Type I Expression in Human CD4+ T Cells Identifies an Early Intermediate in the Differentiation of Th17 from FOXP3+ Naive Regulatory T Cells

D. Valmori, M. Ayyoub, Caroline Raffin, 2011, The Journal of Immunology.

Intermediate in the Differentiation of Th 17 T Cells Identifies an Early + Human CD 4 Ex Vivo IL-1 Receptor Type I Expression in Maha Ayyoub

D. Valmori, M. Ayyoub, Caroline Raffin, 2011 .

Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients1

D. Speiser, P. Romero, V. Cerundolo, 2000, The Journal of Immunology.

Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients.

D. Speiser, P. Romero, D. Valmori, 2001, International immunopharmacology.

CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

K. Odunsi, D. Valmori, J. Matsuzaki, 2012, Cancer research.

Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy

M. Campone, L. Memeo, V. Canzonieri, 2011, PloS one.

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Danila Valmori, Philippe Guillaume, Susan Talbot, 2002, The Journal of clinical investigation.

Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3

P. Romero, V. Cerundolo, D. Valmori, 1999, The Journal of experimental medicine.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

D. Jäger, J. Karbach, L. Old, 2006, Proceedings of the National Academy of Sciences.

Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans

Danila Valmori, Pedro Romero, Daniel E. Speiser, 2002, The Journal of experimental medicine.

Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.

L. Old, D. Valmori, Naira E. Souleimanian, 2005, Clinical immunology.

Therapeutic cancer vaccines based on molecularly defined human tumor antigens.

D. Speiser, P. Romero, M. Pittet, 2002, Vaccine.

Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

D. Valmori, C. Servis, F. Lévy, 2006, Cancer research.

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

D. Speiser, L. Old, D. Valmori, 2004, The Journal of clinical investigation.

Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life

D. Speiser, P. Romero, D. Valmori, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Immunodominance of cytotoxic T lymphocyte epitopes co‐injected in vivo and modulation by interleukin‐12

D. Valmori, G. Eberl, M. Brunda, 1996, European journal of immunology.

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.

J. Karbach, L. Old, D. Valmori, 2007, Clinical immunology.

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

L. Old, D. Valmori, Naira E. Souleimanian, 2006, Clinical immunology.

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.

S. Stevanović, Yao-Tseng Chen, D. Speiser, 2005, Clinical immunology.

MelanomaTumor-Reactive CTL Infiltrating Metastatic SSX-2-Derived Epitope Recognized by Proteasome-Assisted Identification of a

H. Rammensee, S. Stevanović, M. Pfreundschuh, 2002 .

Prevalent Role of TCR α-Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen1

M. Bonneville, P. Romero, P. Coulie, 2003, The Journal of Immunology.

Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTL1

Yingdong Zhao, Clemencia Pinilla, Danila Valmori, 2002, The Journal of Immunology.

Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans

R. Houghten, C. Pinilla, P. Romero, 2002, The Journal of experimental medicine.

Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone.

Yingdong Zhao, Clemencia Pinilla, Danila Valmori, 2002, Cancer research.

Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.

P. Romero, P. Walker, D. Valmori, 2001, Cancer research.

Nonoverlapping T-Cell Receptor Repertoires Lymphocyte-defined Self-Peptide with Diverse and Melanoma Patients Respond to a Cytotoxic T Updated

P. Romero, P. Walker, D. Valmori, 2001 .

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.

P. Romero, D. Valmori, F. Jotereau, 1998, Journal of immunology.

Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content

J. Gu, L. Old, D. Valmori, 2006, Journal of Clinical Immunology.

Findings on T cell specificity revealed by synthetic combinatorial libraries.

Yingdong Zhao, Clemencia Pinilla, Danila Valmori, 2002, Journal of immunological methods.

Distinct Structural TCR Repertoires in Naturally Occurring Versus Vaccine-Induced CD8+ T-Cell Responses to the Tumor-Specific Antigen NY-ESO-1

D. Valmori, E. Jäger, J. Cerottini, 2005, Journal of immunotherapy.

SSX antigens as tumor vaccine targets in human sarcoma.

Yao-Tseng Chen, L. Old, D. Valmori, 2003, Cancer immunity.

Degeneracy instead of specificity: is this a solution to cancer immunotherapy?

D. Speiser, P. Romero, M. Pittet, 2002 .

SSX antigens as cancer vaccines

D. Valmori, 2005 .

Combinatorial peptide library‐based identification of peptide ligands for tumor‐reactive cytolytic T lymphocytes of unknown specificity

Clemencia Pinilla, Danila Valmori, Pedro Romero, 2002, European journal of immunology.

Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma.

F. Izzo, P. Ascierto, L. Buonaguro, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells

K. Odunsi, L. Old, D. Valmori, 2009, Journal of immunotherapy.

T Cells in Tumor Immunity

D. Speiser, P. Romero, M. Pittet, 2003 .

Comment on “A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation”

D. Valmori, M. Ayyoub, Caroline Raffin, 2013, The Journal of Immunology.

Human CD8+ T cells expressing HLA‐DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells

D. Speiser, P. Romero, M. Pittet, 2001, European journal of immunology.